Dermatomyositis Induced by Anti–Tumor Necrosis Factor in a Patient With Juvenile Idiopathic Arthritis | Zendy

Stephanie W. Liu | Zendy; Nicole F. Vélez | Zendy; Christina Lam | Zendy; Alisa N. Femia | Zendy; Scott R. Granter | Zendy; Henry B. Townsend | Zendy; Ruth Ann Vleugels | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dermatomyositis Induced by Anti–Tumor Necrosis Factor in a Patient With Juvenile Idiopathic Arthritis

Author(s) -

Stephanie W. Liu,

Nicole F. Vélez,

Christina Lam,

Alisa N. Femia,

Scott R. Granter,

Henry B. Townsend,

Ruth Ann Vleugels

Publication year - 2013

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2013.5220

Subject(s) - medicine , etanercept , adalimumab , dermatomyositis , infliximab , arthritis , juvenile dermatomyositis , discontinuation , methotrexate , tumor necrosis factor alpha , dermatology , rheumatoid arthritis , immunology

Biologic therapies, including anti-tumor necrosis factor (TNF) agents, are increasingly used to treat a variety of autoimmune diseases. Paradoxically, these agents have been reported to induce some of the very diseases they were designed to treat, including dermatomyositis (DM). We describe the first case of anti-TNF-associated DM without muscle involvement presenting in an adult patient with a history of arthritis since childhood. This cutaneous eruption recurred after rechallenge with an alternate anti-TNF agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research